Group 1 - Bayer's small molecule PRMT5 inhibitor BAY 3713372 has received clinical trial approval in China, targeting MTAP-DEL solid tumors, offering new hope for patients [1] - Eli Lilly's GLP-1 receptor agonist orforglipron has shown positive results in the phase 3 ATTAIN-2 trial for obese adults with type 2 diabetes, achieving significant weight loss and improvements in A1C levels [2] - Ying Shi Biotechnology has submitted an application for an IPO in Hong Kong, focusing on addressing tumor resistance challenges, although the company has not yet commercialized its products and faces financial uncertainties [3] Group 2 - Xinhua Biotechnology has completed a multi-million dollar Series A financing round, with funds aimed at advancing its core pipeline into global clinical trials, highlighting its potential in cancer immunotherapy [4] - Jinfang Pharmaceutical has passed the hearing for its IPO on the Hong Kong Stock Exchange, focusing on developing new treatments for tumors and autoimmune diseases, with a pipeline of eight candidates, five of which are in clinical development [5]